CareDx, Inc. (NASDAQ:CDNA) – Research analysts at Craig Hallum lowered their Q1 2018 earnings per share (EPS) estimates for CareDx in a research report issued to clients and investors on Tuesday. Craig Hallum analyst K. Ellich now anticipates that the company will earn ($0.17) per share for the quarter, down from their prior forecast of ($0.16). Craig Hallum currently has a “Buy” rating and a $10.00 price objective on the stock. Craig Hallum also issued estimates for CareDx’s Q3 2018 earnings at ($0.09) EPS, Q4 2018 earnings at ($0.08) EPS and FY2018 earnings at ($0.47) EPS.

CareDx (NASDAQ:CDNA) last announced its quarterly earnings results on Thursday, August 10th. The company reported ($0.19) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.19). CareDx had a negative return on equity of 85.68% and a negative net margin of 61.27%. The firm had revenue of $12.05 million for the quarter, compared to analysts’ expectations of $11.87 million. WARNING: “Research Analysts Offer Predictions for CareDx, Inc.’s Q1 2018 Earnings (CDNA)” was posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at

Several other analysts also recently issued reports on the company. Raymond James Financial, Inc. raised CareDx from a “market perform” rating to a “buy” rating and set a $6.50 target price on the stock in a research note on Wednesday, September 27th. ValuEngine raised CareDx from a “strong sell” rating to a “sell” rating in a research note on Tuesday, September 26th. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $7.00 price objective (up previously from $3.00) on shares of CareDx in a research note on Tuesday, September 26th. Finally, Zacks Investment Research raised CareDx from a “hold” rating to a “buy” rating and set a $3.25 price objective on the stock in a research note on Tuesday, September 12th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. CareDx has a consensus rating of “Buy” and an average target price of $6.69.

Shares of CareDx (CDNA) traded down 1.71% during midday trading on Friday, hitting $5.76. The stock had a trading volume of 56,138 shares. The firm’s market cap is $129.84 million. The stock’s 50 day moving average price is $3.61 and its 200 day moving average price is $1.82. CareDx has a 12 month low of $0.76 and a 12 month high of $6.69.

In other CareDx news, major shareholder Neil Gagnon acquired 21,448 shares of the company’s stock in a transaction that occurred on Monday, August 28th. The stock was bought at an average price of $2.77 per share, for a total transaction of $59,410.96. Following the acquisition, the insider now directly owns 903,731 shares in the company, valued at $2,503,334.87. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In the last 90 days, insiders have purchased 76,516 shares of company stock valued at $228,586. 5.40% of the stock is owned by company insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Gagnon Securities LLC boosted its holdings in CareDx by 2.9% during the 2nd quarter. Gagnon Securities LLC now owns 2,084,292 shares of the company’s stock valued at $2,314,000 after acquiring an additional 57,954 shares during the period. Royce & Associates LP lifted its holdings in shares of CareDx by 39.3% in the 2nd quarter. Royce & Associates LP now owns 733,287 shares of the company’s stock worth $814,000 after buying an additional 206,815 shares during the period. Finally, Stonepine Capital Management LLC purchased a new stake in shares of CareDx in the 2nd quarter worth $212,000. Institutional investors own 29.13% of the company’s stock.

About CareDx

CareDx, Inc is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.

Receive News & Ratings for CareDx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx Inc. and related companies with's FREE daily email newsletter.